The bivariate probit model of uncomplicated control of tumor: A heuristic exposition of the methodology

International Journal of Radiation Oncology Biology Physics

Volumn 39, Issue 1, 1997, Pages 213-225

  Herbert, Donald ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Bivariate probit model; Dose response models; Extrapolation; Interpolation; Joint probability of uncomplicated control of tumor

Indexed keywords

ARTICLE; CANCER CONTROL; CLINICAL TRIAL; COMPUTER PROGRAM; DOSE RESPONSE; METHODOLOGY; MODEL; ONCOLOGY; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; TUMOR; TUMOR NECROSIS;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MODELS, BIOLOGICAL; NECROSIS; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; PROBABILITY; RADIATION ONCOLOGY; RADIOTHERAPY; TREATMENT FAILURE;

EID: 0030773455     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00084-9     Document Type: Article

References (37)

1. AAPM Report No. 43. Quality assessment and improvement of dose-response models: Some effects of study weaknesses on study findings, "c'est magnifique?" A report of Task Group 1 of the Am. Assoc. of Physicists in Medicine Biological Effects Committee, Madison, WI: Med. Phys. Pub.; 1993.
2. Agren, A.; Brahme, A.; Turesson, I. Optimization of uncomplicated control for head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 19:1077-1085; 1990.
3. Andrews, J. R. Optimization of radiotherapy. Am. J. Clin. Oncol: Cancer Clin. Trials 4:483-495; 1981.
4. Andrews, J. R. Tolerance: An anachronism. Int. J. Radiat. Oncol. Biol. Phys. 12:289-290; 1986.
5. Ashford, F. R.; Sowden, R. R. Multi-variate probit analysis. Biometrics 26:535-546; 1970.
6. Bailar, J. C.; Smith, E. M. Progress against cancer? N. Engl. J. Med. 314:1226-1232; 1986.
7. Box, G. E. P.; Draper, N. R. Evolutionary operation. New York: John Wiley & Sons; 1969.
8. Box, G. E. P.; Wilson, K. B. On the experimental attainment of optimum conditions. J. R. Stat. Soc. B. 13:1951.
9. Cohen, L. Biophysical models in radiation oncology. Boca Raton, FL: CRC Press; 1983.
10. Cohen, L. Optimization of dose-time factors for a tumor and multiple associated normal tissues. Int. J. Radiat. Oncol. Biol. Phys. 13:251-258; 1987.
11. Cohen, L. The statistical prognosis in radiation therapy. A study of optimal dosage in relation to physical and biologic parameters for epidermoid cancer. AJR. 84:741-753; 1960.
12. Cohen, L., Schultheiss, T. E., and Kannaugh, R. C. A Radiation Overdose Incident: Initial Data. Int. J. Radiation Oncology. Biol. Phys. 33:217-224; 1995.
13. Davies, O. L., ed. The design and analysis of industrial experiments. New York: Hafner; 1967.
14. Dische, S. Advances in basic science: Have they benefitted patients with cancer? Br. J. Radiol. 64:1081-1091; 1991.
15. Dische, S. A review of hypoxic cell radiosensitization. Int. J. Radiat. Oncol. Biol. Phys. 20:147-152; 1991.
16. DuMouchel, W. Bayes methods for combining dose-response studies. ASA Conference on Radiation and Health VIII. Proc. of ASA Conference held in Cooper Mountain, CO, July 9-13, 1989. Alexandria, VA: Am. Stat. Assoc. 1990:107-111.
17. Herbert, D. E. Overview of some useful concepts, methods and criteria new to radiobiological modelling : 1) Bivariate Probit Models of Probability of Uncomplicated Local Control of Tumor. 2) An example of the use of the Stein effect. In: Paliwal, B.; Herbert, D.; Fowler, J.; Kinsella, T., eds. Prediction of response in radiation therapy, radiosensitivity and repopulation. Proc. of the 4th Int. Conf. on Dose, Time, and Fractionation in Radiation Oncology. AAPM Sympo. Proc. No. 9. New York: Amer. Inst. Physics; 1993:235.261.
18. Herbert, D. E. Time factors in human tumors: What we know - and when did we know it. How we can learn from data (or fail to). In: Paliwal, B.; Herbert, D.; Fowler, J.; Kinsella, T., eds. Prediction of response in radiation therapy. Radiosensitivity and repopulation. Proc. 4th Intl. Conf. on Dose, Time, and Fractionation in Radia. Oncol. AAPM Sympo. Proc. No. 9. New York: Am. Inst. Physics; 1993:169-214.
19. Kairys, D. The law of clinical testing with human subjects: Legal implications of the new and existing methodologies. In: Kadane, J. B., ed. Bayesian methods and ethics in a clinical trial design. New York: John Wiley & Sons; 1996:223-250.
20. LeSaffre, E.; Molenberghs, G. Multivariate probit analysis: A neglected procedure in medical statistics. Stat. Med. 10:1391-1403; 1991.
21. Metz, C. E.; Tokars, R. P.; Kronman, K. B.; Griem, M. L. Maximum likelihood estimation of dose-response parameters for therapeutic operating characteristic (TOC) analysis of carcinoma of the nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 8:1185-1192; 1982.
22. Montgomery, D. C.; Peck, E. A. Introduction to linear regression analysis, 2nd ed. New York: Wiley & Sons; 1992.
23. Moore, D. H.; Mendelsohn, M. L. Optimal treatment levels in cancer therapy. Cancer 30:97-106; 1972.
24. Oldham, P. D. Measurement in medicine. Philadelphia, PA: J. B. Lippincott; 1968.
25. O'Quigley, J.; Chevret, S. Methods for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study. Stat. Med. 10:1647-1064; 1991.
26. O'Quigley, J.; Pepe, M.; Fisher, L. Continual reassessment method: A practical design for Phase 1 clinical trials in cancer. Biometrics 46:33-48; 1990.
27. Peters, L. J. Through a glass darkly: Predicting the future of radiation oncology. Int. J. Radiat. Oncol. Biol. Phys. 31:219-225; 1995.
28. Pocock, S. J. Statistical and ethical issues in monitoring clinical trials. Stat. Med. 12:1459-1469; 1993.
29. Schultheiss, T. E.; Thames, H. D.; Peters, L. J.; Dixon, D. O. Effect of latency on calculated complication rates. Int. J. Radiat. Oncol. Biol. Phys. 12:1861-1865; 1986.
30. Storer, B. E. Design and analysis of Phase I clinical trials. Biometrics 45:925-937; 1989.
31. Tsiatis, A. A. A Note on a Goodness-of-fit Test for the Logistic Regression Model. Biometrika. 67:250-251; 1980.
32. United States General Accounting Office. Cross-design synthesis. A new strategy for medical effectiveness research. U.S. General Accounting Office, Gaithersburg, MD. 1992.
33. Van den Bogaert, W.; van der Schueren, E.; Horiot, J.; De Vilhena, M.; Schruab, S.; Svoboda, V.; Arcangeli, G.; de Pauw, M.; Van Glabbeke, M. The EORTC randomized trial on three fractions per day and misonidazole (Trial No. 22811) in advanced head and neck cancer: Long-term results and side effects. Radiother. Oncol. 35:91-99; 1995.
34. Whitehead, J.; Brunier, H. Bayesian decision procedures for dose determining experiments. Stat. Med. 14:885-893; 1995.
35. Withers, H. R. Contrarian concepts in the progress of radiotherapy. Radiat. Res. 119:395-412; 1989.
36. Withers, H. R.; Taylor, J. M. G.; Maciejewski, B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:131-146; 1988.
37. Yaes, R. J. Some implications of the linear quadratic model for tumor control probability. Int. J. Radiat. Oncol. Biol. Phys. 14:147-157; 1988.